Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension.

Digiuni M, Manni G, Vetrugno M, Uva M, Milano G, Orzalesi N, Fogagnolo P, Centofanti M, Campos E, Rossetti L.

J Glaucoma. 2013 Dec;22(9):707-12. doi: 10.1097/IJG.0b013e318259b47c.

PMID:
22595934
2.
3.

Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension.

Sanford M.

Clin Drug Investig. 2014 Jul;34(7):521-8. doi: 10.1007/s40261-014-0203-4. Review.

PMID:
24895141
4.

Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.

Kaufman PL.

Expert Opin Pharmacother. 2017 Mar;18(4):433-444. doi: 10.1080/14656566.2017.1293654. Epub 2017 Feb 20. Review.

PMID:
28234563
5.

Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.

Keating GM.

Clin Drug Investig. 2016 Jun;36(6):499-508. doi: 10.1007/s40261-016-0413-z. Review.

PMID:
27225879
6.

Prostaglandin analogs in the treatment of glaucoma.

Hejkal TW, Camras CB.

Semin Ophthalmol. 1999 Sep;14(3):114-23. Review.

PMID:
10790575
7.

Upper limits of intraocular pressure in glaucoma clinical trials.

DeMill DL, Wirostko BM, Nelson LA, Stewart WC.

Clin Exp Ophthalmol. 2015 Jan-Feb;43(1):84-5. doi: 10.1111/ceo.12357. Epub 2014 May 30. Review. No abstract available.

8.

[Research progress of the side effect of the prostaglandin drugs].

Liu XY, Tang L, Peng YH, Chen XM, Wang NL.

Zhonghua Yan Ke Za Zhi. 2013 Nov;49(11):1045-8. Review. Chinese.

PMID:
24555212

Supplemental Content

Support Center